2004 Cannabinoids Clinical Trials Consumption 
Greencamp
AUGUST 16, 2018
Exploring the available research on ALS and cannabinoids. The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. The first study I will reference is from 2006, conducted on mice.
The Cannigma
JANUARY 13, 2023
Treating migraine pain is one of the instances where inhaled cannabis consumption, such as smoking or vaping , is important for the right effects and speed of delivery. 4 A 2004 study found that the endocannabinoid anandamide can inhibit trigeminal neurons, which suggests a way in which endocannabinoids may be able to prevent migraines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 24, 2021
The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). These were news stories focusing on the use of cannabinoids for chronic cancer pain or inhibiting tumour growth, and mental illness. 2016 ; Sznitman et al. Discussion.
Cannabis Law Report
OCTOBER 29, 2019
Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.
Cannabis Law Report
JULY 12, 2019
International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.
Expert insights. Personalized for you.
94 
Let's personalize your content